Paclitaxel (Taxol®)-induced apoptosis in human epithelioid sarcoma cell lines is enhanced by upregulation of CD95 ligand (FasL/Apo-1L)

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 6, 2008, Pages 689-695

  Heikaus, Sebastian ^a   Matuszek, Krystian S ^a   Suschek, Christoph V ^b   Ramp, Uwe ^a   Reinecke, Petra ^a   Grinstein, Edgar ^a   Haremza, Janine ^a   Gabbert, Helmut E ^a   Mahotka, Csaba ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Apoptosis; CD95 ligand; Epithelioid sarcoma; Paclitaxel

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN A1; DEATH RECEPTOR; FAS ANTIGEN; FAS LIGAND; FLUOROURACIL; LIPOCORTIN 5; PACLITAXEL; MESSENGER RNA;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; CELL DEATH; CELL SUBPOPULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG RESPONSE; ENZYME ACTIVATION; EPITHELIOID SARCOMA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; METASTASIS; MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STAINING; UPREGULATION; WESTERN BLOTTING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SARCOMA; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; FAS LIGAND PROTEIN; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PACLITAXEL; RNA, MESSENGER; SARCOMA; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 41849127108     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0340-8     Document Type: Article

References (20)

1. Chase DR, Enzinger FM (1985) Epithelioid sarcoma. Diagnosis, prognostic indicators, and treatment. Am J Surg Pathol 9:241-263
2. Dejosez M, Ramp U, Mahotka C, Krieg A, Walczak H, Gabbert HE, Gerharz CD. (2000) Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Cell Death Differ 7:1127-1136
3. Eichhorst ST, Muller M, Li-Weber M, Schulze-Bergkamen H, Angel P, Krammer PH (2000) A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol Cell Biol 20:7826-7837
4. Engers R, Gerharz CD, Moll R, Pohl A, Sarbia M, Gabbert HE (1994) Interclonal heterogeneity in a human epithelioid-sarcoma cell line (GRU-1). Int J Cancer 59:548-553
5. Engers R, van Roy F, Heymer T, Ramp U, Moll R, Dienst M, Friebe U, Pohl A, Gabbert HE, Gerharz CD. (1996) Growth inhibition in clonal subpopulations of a human epithelioid sarcoma cell line by retinoic acid and tumour necrosis factor alpha. Br J Cancer 73:491-498
6. Enzinger FM (1970) Epitheloid sarcoma. A sarcoma simulating a granuloma or a carcinoma. Cancer 26:1029-1041
7. Evans HL, Baer SC (1993) Epithelioid sarcoma: a clinicopathologic and prognostic study of 26 cases. Semin Diagn Pathol 10:286-291
8. Friesen C, Herr I, Krammer PH, Debatin KM (1996) Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2: 574-577
9. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM (1997a) The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 57:3823-3829
10. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nuñez G, Krammer PH, Peter ME, Debatin KM. (1997b) Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 57:4956-4964
11. Fulda S, Los M, Friesen C, Debatin KM (1998a) Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer 76:105-114
12. Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME, Debatin KM (1998b) Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma- irradiation-induced apoptosis of brain tumor cells. Cell Death Differ 5:884-893
13. Gerharz CD, Ramp U, Dejosez M, Mahotka C, Czarnotta B, Bretschneider U, Lorenz I, Müller M, Krammer PH, Gabbert HE. (1999) Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control. Lab Invest 79:1521-1534
14. Halling AC, Wollan PC, Pritchard DJ, Vlasak R, Nascimento AG (1996) Epithelioid sarcoma: a clinicopathologic review of 55 cases. Mayo Clin Proc 71:636-642
15. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR. (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99:403-413
16. Reinecke P, Knopf C, Schmitz M, Schneider EM, Gabbert HE, Gerharz CD (2000a) Growth inhibitory effects of paclitaxel on human epithelioid sarcoma in vitro: heterogeneity of response and the multidrug resistance phenotype. Cancer 88:1614-1622
17. Ross HM, Lewis JJ, Woodruff JM, Brennan MF (1997) Epithelioid sarcoma: clinical behavior and prognostic factors of survival. Ann Surg Oncol 4:491-495
18. Stumm S, Meyer A, Lindner M, Bastert G, Wallwiener D, Gückel B. (2004) Paclitaxel treatment of breast cancer cell lines modulates Fas/Fas ligand expression and induces apoptosis which can be inhibited through the CD40 receptor. Oncology 66:101-111
19. Wang TH, Popp DM, Wang HS, Saitoh M, Mural JG, Henley DC, Ichijo H, Wimalasena J. (1999) Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem 274:8208-8216
20. Wang TH, Wang HS, Soong YK (2000) Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 88:2619-2628